Trimebutine is a drug with antimuscarinic and very weak mu opioid agonist effects. It is used for the treatment of irritable bowel syndrome and other gastrointestinal disorders. It is sometimes combined with simethicone as a combination drug. Trimebutine acts primarily by modulating gastrointestinal motility through peripheral opioid receptor activity and partial antagonism of cholinergic pathways, producing spasmolytic and prokinetic effects depending on baseline gut tone; the maleate salt is the common pharmaceutical form and the compound is characterized by good oral absorption and hepatic metabolism with multiple phase I and II metabolites. Trimebutine + some more technical info
Parent: Trimebutine
Parent: Trimebutine
Parent: Trimebutine
Parent: Trimebutine
Parent: Trimebutine/ Trimebutine Maleate
Parent: Trimebutine
Parent: Trimethoprim / Trimebutine
Parent: Trimethoprim / Trimebutine
Parent: Trimebutine
Quality control of trimebutine follows ICH impurity guidance and typical batch specifications set limits for related substances and residual solvents; typical analytical acceptance criteria used by manufacturers are reporting thresholds at 0.05 percent and specification limits that commonly allow individual unidentified impurities up to 0.10 to 0.20 percent and total impurities not to exceed 1.0 percent by area on validated HPLC methods. Known related compounds include de-esterification products, O- or N-dealkylated metabolites, minor transesterification or rearrangement products and trace amounts of starting-material related amines; specific limits for known related impurities are often set in the 0.05 to 0.5 percent range depending on toxicological assessment. Residual solvents are controlled per ICH Q3C, for example methanol up to 3000 ppm for class 2 solvents, and dichloromethane typically limited to 600 ppm, while inorganic counterion-related species such as maleate are monitored by assay and identity tests rather than listed as organic impurities.
Trimebutine is used to treat functional gastrointestinal disorders, most commonly irritable bowel syndrome, by reducing abdominal cramping and normalizing bowel motility; it may also be prescribed for other spasm-related or disordered-motility conditions of the gut, sometimes in combination with simethicone when excess gas is present.
Duration of trimebutine therapy should be determined by a treating physician based on symptom response and safety monitoring; it is often prescribed for short to medium term symptom control (weeks to months) and long-term use can be considered only under medical supervision with periodic reassessment, particularly if symptoms persist or if there are concerns about liver function or drug interactions.
Trimebutine has very weak mu opioid agonist activity at peripheral opioid receptors in the gut but is not a classical central opioid analgesic; its antispasmodic and prokinetic effects derive from a combination of this weak opioid activity and antimuscarinic modulation of gastrointestinal smooth muscle.
Yes, trimebutine can reduce abdominal pain and cramping associated with irritable bowel syndrome and other functional gut disorders by decreasing spasmodic contractions and normalizing motility, but relief varies between patients and should be evaluated by a clinician as part of an overall treatment plan.
